Home › Trials › NCT04161417

Personalizing treatment for pancreatic cancer

Precision-Panc Master Protocol: Personalising Treatment For Pancreatic Cancer

Not applicable Interventional University of Glasgow · NCT04161417

This study is testing whether personalizing treatment for pancreatic cancer based on individual tumor characteristics can help patients get better care and improve their outcomes.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment2500 (estimated)
Ages16 Years and up
SexAll
SponsorUniversity of Glasgow Academic / other
Drugs / interventionschemotherapy
Locations33 sites (Aberdeen and 32 other locations)
Trial IDNCT04161417 on ClinicalTrials.gov

What this trial studies

The Precision-Panc Master Protocol is designed to enroll patients with known or suspected pancreatic cancer across multiple centers in the UK. Participants will provide tumor biopsy and blood samples for molecular profiling, which will help inform their eligibility for various treatment regimens in the PRIMUS studies. This approach aims to tailor treatment based on individual molecular characteristics, potentially improving outcomes for patients with pancreatic cancer.

Who should consider this trial

Good fit: Ideal candidates include adults over 16 with suspected or confirmed pancreatic cancer who are willing to undergo additional tumor biopsies for molecular profiling.

Not a fit: Patients with pancreatic cancer who are not suitable for chemotherapy, radiotherapy, or surgery may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to more personalized and effective treatment options for patients with pancreatic cancer.

How similar studies have performed: Other studies utilizing molecular profiling for personalized treatment in cancer have shown promise, indicating a potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Adult patients (age \>16 years).
* Either:

  * Presence of a hypodense pancreatic mass highly suspicious of primary pancreatic cancer with or without distant metastasis as assessed by a Pancreatic Multi-Disciplinary Team (MDT).

Or

o Histologically or cytologically confirmed pancreatic ductal adenocarcinoma and its variants.

* Patient is willing and able to undergo additional tumour biopsy (from the primary or a metastatic site) aimed at obtaining sufficient tissue for molecular profiling if this is required.
* Patient is deemed suitable to receive chemotherapy and/or radiotherapy, and/or surgery pending stage of disease at presentation.
* Patient is deemed potentially eligible for a currently open PRIMUS study
* Patient has signed informed consent for screening research tumour biopsy (Consent 1).
* Patient has signed informed consent for Precision-Panc Master Protocol molecular profiling (Consent 2).

Where this trial is running

Aberdeen and 32 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Neoplasms Pancreatic
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.